An insight into novel third-generation TLR2 co-stimulatory CAR-T cells

In this video, Yasmin Nouri, BSc, MSc, Malaghan Institute of Medical Research, Wellington, New Zealand, shares some insights into the development of a novel third-generation TLR2 co-stimulatory CAR-T cell product for the treatment of B-cell malignancies, which has demonstrated promising activity in a Phase I clinical trial. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.